IL313864A - Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1 - Google Patents
Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1Info
- Publication number
- IL313864A IL313864A IL313864A IL31386424A IL313864A IL 313864 A IL313864 A IL 313864A IL 313864 A IL313864 A IL 313864A IL 31386424 A IL31386424 A IL 31386424A IL 313864 A IL313864 A IL 313864A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- muc16
- methods
- combination
- ovarian cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263297333P | 2022-01-07 | 2022-01-07 | |
| US202263342542P | 2022-05-16 | 2022-05-16 | |
| US202263394483P | 2022-08-02 | 2022-08-02 | |
| US202263421541P | 2022-11-01 | 2022-11-01 | |
| PCT/US2023/010326 WO2023133280A1 (en) | 2022-01-07 | 2023-01-06 | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313864A true IL313864A (en) | 2024-08-01 |
Family
ID=85199214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313864A IL313864A (en) | 2022-01-07 | 2023-01-06 | Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230312718A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4460520A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025502061A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240130137A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023204751A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242629A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313864A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008055A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023133280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102531251B1 (ko) * | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| TW202542187A (zh) * | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| TW202504917A (zh) * | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
-
2023
- 2023-01-06 MX MX2024008055A patent/MX2024008055A/es unknown
- 2023-01-06 KR KR1020247026382A patent/KR20240130137A/ko active Pending
- 2023-01-06 CA CA3242629A patent/CA3242629A1/en active Pending
- 2023-01-06 EP EP23703960.7A patent/EP4460520A1/en active Pending
- 2023-01-06 JP JP2024540882A patent/JP2025502061A/ja active Pending
- 2023-01-06 IL IL313864A patent/IL313864A/en unknown
- 2023-01-06 WO PCT/US2023/010326 patent/WO2023133280A1/en not_active Ceased
- 2023-01-06 AU AU2023204751A patent/AU2023204751A1/en active Pending
- 2023-01-06 US US18/094,176 patent/US20230312718A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230312718A1 (en) | 2023-10-05 |
| MX2024008055A (es) | 2024-09-06 |
| KR20240130137A (ko) | 2024-08-28 |
| JP2025502061A (ja) | 2025-01-24 |
| EP4460520A1 (en) | 2024-11-13 |
| WO2023133280A1 (en) | 2023-07-13 |
| AU2023204751A1 (en) | 2024-07-11 |
| CA3242629A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279251A (en) | Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1 | |
| MX2024009277A (es) | Anticuerpos anti proteina de muerte programada 1 (pd-1) y usos de estos. | |
| MX2020002301A (es) | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. | |
| IL319877A (en) | Methods for treating cancer with bispecific EGFR X CD28 antibodies alone or in combination with anti-PD-1 antibodies | |
| IL315405A (en) | Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies | |
| IL292662A (en) | Methods for treating cancer with a combination of an anti-pd-1 antibody and a drug-anti-tissue factor antibody conjugate | |
| IL318426A (en) | Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies | |
| EP4104855A4 (en) | USE OF AN ANTI-PD-1 ANTIBODY IN THE TREATMENT OF NEUROENDOCRINE TUMORS | |
| IL319944A (en) | Methods of using anti-CTLA4 antibody to treat colon cancer | |
| CA3242629A1 (en) | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies | |
| CA3261147A1 (en) | DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES | |
| HK40118892A (en) | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies | |
| IL312813A (en) | Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4 | |
| IL316751A (en) | Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and anti-CD3 alone or in combination with anti-PD-1 antibodies | |
| HK40122871A (en) | Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies | |
| MX2023011796A (es) | Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit). | |
| HK40130891A (en) | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies | |
| CA3269085A1 (en) | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies | |
| IL315307A (en) | Treatment methods using CTLA-4 and PD-1 bispecific antibodies | |
| IL318036A (en) | Bispecific anti-PCRV and PSL antibodies for the treatment of bronchiectasis | |
| HK40122754A (en) | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies | |
| CA3306323A1 (en) | Anti-pd-l1 and anti-4-1bb bispecific antibody for treating tumors | |
| HK40128565A (zh) | 使用双特异性抗psma×抗cd28抗体与抗pd-1抗体组合来治疗转移性去势抵抗性前列腺癌的方法 | |
| HK40101290A (en) | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody | |
| IL315653A (en) | Methods for treating bile duct cancer using ANTI-PD-L1 antibody in combination with chemotherapy |